ArticlePharmaceutical research2006
Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence.
Article in Pharmaceutical research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Advancing liposome technology for innovative strategies against malaria.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- A Comparison of Cellular Uptake Mechanisms, Delivery Efficacy, and Intracellular Fate between Liposomes and Extracellular Vesicles.Advanced healthcare materials · 2023Review
- Circumsporozoite Protein ofPharmaceutics · 2022Article
- Liposomes for malaria management: the evolution from 1980 to 2020.Malaria journal · 2021Review
- A Review of Nanotechnology for Targeted Anti-schistosomal Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- Nano-biotechnology: a new approach to treat and prevent malaria.International journal of nanomedicine · 2019Review
- Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.Scientific reports · 2017Article
- Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies.Drug delivery and translational research · 2016Review
- A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo.Molecular therapy. Nucleic acids · 2016Article
- High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo.BMC biotechnology · 2015Article
- Use of labeled tomato lectin for imaging vasculature structures.Histochemistry and cell biology · 2015Article
- IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathway.BioMed research international · 2015Article
- Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors.Nanoscale research letters · 2011Article
- Characterization of Kupffer cells in livers of developing mice.Comparative hepatology · 2011Article
- Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate.International journal of pharmaceutics · 2009Article
- Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis.Histochemistry and cell biology · 2009Article
- Nanoconjugate based on polymalic acid for tumor targeting.Chemico-biological interactions · 2008Article
- Interfering with disease: a progress report on siRNA-based therapeutics.Nature reviews. Drug discovery · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeSeveral species of the protozoan Plasmodium effectively target mammalian liver during the initial phase of host invasion. The purpose of this study was to demonstrate that a Plasmodium targeting amino acid sequence can be engineered into therapeutic nanoparticle delivery systems.
methodsA 19-amino peptide from the circumsporozoite protein of Plasmodium berghei was prepared containing the conserved region I as well as a consensus heparan sulfate proteoglycan binding sequence. This peptide was attached to the distal end of a lipid-polyethylene glycol bioconjugate. The bioconjugate was incorporated into phosphatidylcholine liposomes containing fluorescently labeled lipids to follow blood clearance and organ distribution in vivo.
resultsWhen administered intravenously into mice, the peptide-containing liposomes were rapidly cleared from the circulation and were recovered almost entirely in the liver. Fluorescence and electron microscopy demonstrated that the liposomes were accumulated both by nonparenchymal cells and hepatocytes, with the majority of the liposomal material associated with hepatocytes. Accumulation of liposomes in the liver was several hundredfold higher compared to heart, lung, and kidney, and more than 10-fold higher compared to spleen. In liver slice experiments, liposome binding was specific to sites sensitive to heparinase.
conclusionsIncorporation of amino acid sequences that recognize glycosaminoglycans is an effective strategy for the development of targeted drug delivery systems.
Indexed as
Identifiers
16550476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.